100% Quality Guarantee
PhD-Level Technical Support
Anti-TIGIT vibostolimab biosimilar mAb HDBS0027
Key Features

Vibostolimab Biosimilar (TIGIT) Antibody (HDBS0027)

SKU HDBS0027
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein TIGIT
Reactivity Human
Host Species Humanized
Isotype IgG1
$569

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Vibostolimab Biosimilar (TIGIT) Antibody (HDBS0027)

The TIGIT (Vibostolimab) Biosimilar Monoclonal Antibody (HDBS0027) is a cutting-edge tool for researchers investigating the TIGIT protein, a key player in immune regulation and a potential target for cancer therapy. This antibody, produced using advanced biosimilar technology, shows high specificity for TIGIT in human samples and is validated for use in various applications, including immunohistochemistry and flow cytometry.TIGIT, also known as T cell immunoreceptor with Ig and ITIM domains, is a co-inhibitory receptor that plays a crucial role in regulating T cell activity and immune responses. Its interaction with ligands such as CD155 and CD112R on antigen-presenting cells helps to dampen immune responses and promote immune tolerance.

Targeting TIGIT has emerged as a promising strategy for enhancing anti-tumor immune responses and overcoming immune evasion in cancer.The Anti-TIGIT (Vibostolimab) Biosimilar Monoclonal Antibody (HDBS0027) offers researchers a reliable tool to study TIGIT expression and function in various cell types and disease models. Its use can contribute to the development of novel immunotherapies for cancer and other immune-related disorders by uncovering the underlying mechanisms of TIGIT-mediated immune regulation.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose